
|Videos|December 16, 2021
New Delivery Option for Ketamine
Author(s)Jeffrey Becker, MD
How can new formulations of ketamine impact patient care?
Advertisement
Jeffrey Becker, MD, discusses new formulations of ketamine for subcutaneous delivery and how ketamine works.
Dr Becker is cofounder and Chief Scientific Officer at Bexson Biomedical, Inc.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial: The Power of Another COMP360 Dose
2
The Postmodern Worldview and Contemporary Psychiatry
3
New Phase 2 Clinical Trial Initiating in 2027: Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
4
DT120 (Lysergide) ODT Receives Breakthrough Therapy Designation for Treatment of MDD
5







